Cue Biopharma
Ron Seidel is co-founder of Cue Biopharma and co-inventor of several of its core technologies. He currently serves as Senior Scientific Advisor to Cue Biopharma. From the Company’s formation in 2015 through June of 2021, Dr. Seidel had oversight of daily Company operations integrating R&D and intellectual property (IP) development strategy with operational capabilities and scientific direction. Specifically, he leveraged his expertise in molecular engineering toward the generation of new high-value assets. Prior to Cue Biopharma, Dr. Seidel was a Research Assistant Professor of Biochemistry and Associate Director of the Macromolecular Therapeutic Development Facility (MTDF) at the Albert Einstein College of Medicine. The function of the MTDF was to leverage high throughput technologies for the development, analysis, and production of protein-based therapeutics. Additionally, through the MTDF, Dr. Seidel was the Associate Director of Eukaryotic Protein Production at the Northeast BioDefense Center (NBC). He has also served as a consultant to the industry in biologics and protein production. Dr. Seidel holds a B.S. and Ph.D. in Biochemistry from the University of Georgia. He did his post-doctoral work at the New York Structural Biology Center.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Cue Biopharma
1 followers
Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.